CORP DEV TECHNOLOGY ANALYSIS

CORP DEV TECHNOLOGY ANALYSIS

Performed technology analysis, technical diligence, and post-acquisition integration activities, as well as provided corporate and business strategy input, in support of over $400M in acquisitions by pioneering synthetic biology and genetic engineering company Intrexon. Supported internal development programs for first-in-class products reviewed by FDA, USDA, EPA, and USFWS regulators. Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance business and new product development.
Performed technology analysis, technical diligence, and post-acquisition integration activities, as well as provided corporate and business strategy input, in support of over $400M in acquisitions by pioneering synthetic biology and genetic engineering company Intrexon. Supported internal development programs for first-in-class products reviewed by FDA, USDA, EPA, and USFWS regulators. Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance business and new product development.

TECHNOLOGY ANALYSIS | M&A DILIGENCE | CORPORATE STRATEGY | TECHNOLOGY INNOVATION

  • AquaBounty genetically engineered (GE) salmon, first GE food animal FDA approved for human consumption (partial acquisitions)
  • Oxitec engineered insects to fight infectious disease, invasive species, and agricultural pests ($160M acquisition)
  • Trans Ova Genetics leading provider of bovine reproductive technologies for food production ($110M acquisition)
  • ViaGen cloning for food and companion animals, as well as endangered species conservation (Trans Ova Genetics acquisition) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (technology acquisition and joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec viral-based vaccine platform for humans and animals (acquisition)
  • Intrexon molecular vaccine and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® protein engineering and gene switch platforms for clinical, industrial, and agricultural applications [microbes, plants, animals, humans]
  • Intrexon’s pioneering of gene-edited environmental systems for bioremediation of emerging contaminants of concern (e.g., 1,4-dioxane)
TECHNOLOGY ANALYSIS | M&A DILIGENCE | CORPORATE STRATEGY | TECHNOLOGY INNOVATION

  • AquaBounty genetically engineered (GE) salmon, first GE food animal FDA approved for human consumption (partial acquisitions)
  • Oxitec engineered insects to fight infectious disease, invasive species, and agricultural pests ($160M acquisition)
  • Trans Ova Genetics leading provider of bovine reproductive technologies for food production ($110M acquisition)
  • ViaGen cloning for food and companion animals, as well as endangered species conservation (Trans Ova Genetics acquisition) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (technology acquisition and joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec viral-based vaccine platform for humans and animals (acquisition)
  • Intrexon molecular vaccine and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® protein engineering and gene switch platforms for clinical, industrial, and agricultural applications [microbes, plants, animals, humans]
  • Intrexon’s pioneering of gene-edited environmental systems for bioremediation of emerging contaminants of concern (e.g., 1,4-dioxane)
Return to MY WORK | MISSION
Return to MY WORK | MISSION